Introduction {#s1}
============

Status epilepticus (SE) is a relatively common and life-threatening neurological emergency with an estimated incidence of up to 61 episodes per 100,000 population per year ([@B8]; [@B64]). The overall mortality rate of refractory SE is 17% to 27%, and up to 36% in super-refractory SE ([@B11]; [@B26]). Predictably, its substantial morbidity and mortality could incur high health care costs. The total direct and indirect costs for epilepsy in Europe would add up to €13.8 billion per year, of which SE was an important source of direct costs ([@B48]). In Germany, the average cost of hospitalization for SE was €14,946 per patient per admission with a mean length of stay was 19 days, and super-refractory SE (SRSE) was the main cost-drive with the estimated cost up to €50,488 ([@B32]). The total cost of direct hospitalization in the United States (US) caused by SE each year was even as high as \$4 billion ([@B49]). The International League against Epilepsy (ILAE)\'s updated definition of SE in 2015 highlights the long-term effects of prolonged seizure activity on the nervous system, including neuronal death and neuronal injury ([@B65]). Therefore, the key of SE treatment strategy is to identify and terminate seizure activities as early as possible before irreversible neuronal damage occurs ([@B64]).

Currently, there is high level evidence only for the first-line medications of SE including intravenous (IV) benzodiapines (preferably lorazepam, LOR) ([@B60]; [@B40]; [@B12]; [@B21]). But first-line therapy may fail to control at least 30%--40% of the time and LOR could not be obtained in some countries or areas, alternative treatment is necessary ([@B2]; [@B66]). Some of the conventional agents including phenytoin (PHT), phenobarbital (PB), and valproate (VPA) were available as second-line treatment. However, toxicity limited the applications, such as hypotension and respiratory suppression in PB, and hepatic injury in VPA ([@B57]; [@B67]). Therefore, newer, more effective and less toxic drugs for management of SE were needed. More recently, some new anti-epileptic drugs (AEDs) with IV dosage form, such as levetiracetam (LEV) and laconamide, have been used as alternative AEDs for the treatment of SE ([@B50]; [@B68]).

In 1999, LEV was approved as adjunctive therapy for adults with focal epilepsy in the US. In 2006, the US Food and Drug Administration approved IV LEV for patients above 16 years old when oral treatment was not feasible. Since then, efficacy of IV LEV has been reported in many open-label case-series in adults and children with SE. And some retrospective studies that have suggested LEV as an effective treatment for various forms of SE as a first- or second-, or third-line treatment ([@B7]; [@B43]; [@B63]; [@B69]; [@B28]). Current researches suggested that LEV may bind to the synaptic vesicle protein 2A, and thus depressed the epilepsy discharge through participating in the exocytosis of synaptic vesicles and regulating the release of neurotransmitters (especially the excitatory amino acids) ([@B54]; [@B37]; [@B16]). LEV has a favorable pharmacokinetic profile. No clinically significant interactions with other AEDs were found since LEV is mainly renal excreted unchanged independent of liver cytochrome P450 ([@B18]) Compared to many other AEDs, LEV had fewer reported adverse events (AEs), but this may be because of its relatively short period of clinical use ([@B63]; [@B68]). In recent years, apart from psychiatric and behavioral side effects ([@B73]), some rare AEs of LEV including rhabdomyolysis, thrombocytopenia and anaphylaxis were reported ([@B31]; [@B17]; [@B29]).

Thus, we conducted a systematic review (SR) and meta-analysis to evaluate the evidence on the efficacy, safety and economic benefits of IV LEV compared with all other AEDs for SE.

Materials and Methods {#s2}
=====================

Search Strategy {#s2_1}
---------------

We searched PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and OpenGrey.eu from inception to July 19^th^ 2018 and updated the search results till June 12^th^, 2019. The following keywords were used in search terms for relevant literatures of LEV: "status epilepticus," "epilepsy," "seizures," and "epileptic\*" for the disease, and terms "Keppra," "levetiracetam," "Desitrend," "Spritam," "Kepcet," "Kevtam," "Levitam," "injection," and "intravenous" for the medication. We used the Boolean logic "AND" to combine the two sets of terms. The study was registered on PROSPERO (No. CRD 42017069367).

Study Selection and Outcome Measures {#s2_2}
------------------------------------

Two independent authors (X-LZ and M-LW) screened all retrieved records for potentially eligible studies manually by title and abstract screening in the first stage, and the full-text screening secondly. During the title and abstract screening, studies that may meet the inclusion criteria, or need further information for a clear judgment were included for a full-text screening process. Studies were included if: (1) enrolled SE patients, (2) compared the efficacy, safety or economic profiles of IV LEV against all other anticonvulsants for SE, with no restriction to dosage and duration, and (3) SR, meta-analysis, randomized controlled trials (RCTs), observational studies (cohort and case--control studies, case reports, and case series) and economic studies were considered. Studies were excluded if: (1) original data was not presented (for example, comments and expert opinions), (2) published in non-English languages without required data translated into English, and (3) data extraction/interpretation was not possible. Disagreements was resolved through discussion, and a third party was consulted and discussed (Z-MY) if necessary.

The primary efficacy outcomes focused on SE cessation. The secondary efficacy outcomes included seizures freedom within 24 h, neurological outcome at discharge, need for ventilator assistance, and mortality during hospitalization, discontinuation due to AEs, serious AEs, total AEs, single AEs, and cost-effectiveness.

Data Extraction and Quality Assessment {#s2_3}
--------------------------------------

Two independent investigators (X-LZ and M-LW) performed data extraction according to a pre-designed data collection form. Information including authors, publication year, number of LEV trials, participant characteristics (participation-eligibility criteria, gender and age), dosage, treatment duration, outcomes of interest, and drop-out rate were extracted.

Methodological quality of included studies was independently assessed by the two investigators. The quality of included SRs was assessed with the Assessment of Multiple Systematic Reviews tool (range, 0\~11) ([@B59]). The risk of bias in the eligible RCTs was assessed with the Cochrane risk of bias assessment tool ([@B23]). The quality of the eligible economic study was assessed with consolidated health economic evaluation reporting standard (CHEERS) ([@B24]) We did not conduct a quality assessment of the included observational studies. The authors of eligible studies were contacted for clarifications if there was missing data. We resolved all disagreements about data extraction and quality assessment through discussion among all authors.

Statistical Analysis {#s2_4}
--------------------

Treatment effect of RCTs evaluating similar interventions in similar participants was pooled using random-effect model through meta-analyses in an intention to treat manner (following the allocation of participants in studies) with RevMan 5.3 software. The odds ratio (OR) for categorical outcomes was calculated. *P* \< 0.05 was considered statistically significant. Safety outcomes of observational studies were described and numbers of case reports as well as case-series was pooled by classification of AEs. Statistical heterogeneity was assessed with the Mantel-Haenszel chi-square test and quantified with the *I*^2^ test.

Results {#s3}
=======

Study Selection {#s3_1}
---------------

There were 435 relevant studies identified in the initial search, and 43 studies were identified in the updated search. After duplicates removed, we screened 409 title and abstract records. Of these, 288 studies were excluded after title/abstract screening, and 104 studies were selected for full-text review. And 43 reports met the inclusion criteria after full-text review: 5 SRs/meta-analyses ([@B34]; [@B74]; [@B51]; [@B72]; [@B10]), 9 RCTs ([@B42]; [@B13]; [@B44]; [@B45]; [@B22]; [@B61]; [@B14]; [@B36]; [@B46]), 1 non randomized trial ([@B69]), 27 case series/reports ([@B19]; [@B5]; [@B41]; [@B55]; [@B1]; [@B7]; [@B9]; [@B30]; [@B43]; [@B71]; [@B15]; [@B47]; [@B53]; [@B70]; [@B28]; [@B62]; [@B4]; [@B39]; [@B52]; [@B25]; [@B31]; [@B3]; [@B33]; [@B6]; [@B29]; [@B38]; [@B58]), and 1 economic study ([@B56]) ([**Figure 1**](#f1){ref-type="fig"}).

![PRISMA flow diagram for literature search and study selection.](fphar-11-00751-g001){#f1}

Study Characteristics and Quality Assessment {#s3_2}
--------------------------------------------

The included SRs published between 2012 and 2016, enrolling patients with convulsive SE, non-convulsive SE and refractory SE. Two SRs compared LEV with VPA ([@B34]; [@B10]), 1 SR compared LEV with PHT ([@B10]), 1 SR compared LEV with LOR ([@B51]) and 2 SRs evaluated the efficacy of LEV as first or second-line therapy in SE ([@B74]; [@B72]) Among the two SRs, one SR evaluated the efficacy of five AEDs (included LEV) as a second-line therapy in benzodiazepine-resistant SE ([@B72]), another one evaluated LEV as a first-line AED, as single treatment or combined with benzodiazepines ([@B74]). Characteristics of included SRs were showed in [**Table 1**](#T1){ref-type="table"}.

###### 

The characteristics of included systematic reviews.

  Author, year   Last search time   Patients                                                                                         Studies   Cases   Intervention group                 Control group   Outcome measures
  -------------- ------------------ ------------------------------------------------------------------------------------------------ --------- ------- ---------------------------------- --------------- ----------------------------------------------------------------------------------------------------------------
  [@B10]         2015.10            Convulsive SE (generalized or focal) persisting despite first-line BZDs in patients of any age   2         194     LEV                                PHT/VPA         Number of patients with SE cessation within 15 min after the start of drug administration
  [@B34]         2010.11            All patients above 14 years old with refractory SE                                               1         82      LEV                                VPA             SE cessation
  [@B51]         2013.08            Premonitory or early stage SE or established SE                                                  1         79      LEV                                LOR             SE cessation; seizure recurrence within 24 h; hypotension; respiratory failure; death; ventilatory requirement
  [@B72]         Not reported       Benzodiazepine-resistant convulsive SE                                                           8         204     LEV                                Not reported    SE cessation
  [@B74]         2011.01            Adults with SE                                                                                   10        334     LEV combined with benzodiazepine   LEV alone       SE cessation; adverse events

BZDs, benzodiazepines; LEV, levetiracetam; LOR, lorazepam; PHT, phenytoin; SE, status epilepticus; VPA, valproate.

Among the included RCTs, 6 compared LEV with PHT for second-line treatment ([@B13]; [@B44]; [@B22]; [@B61]; [@B14]; [@B36]), 2 compared LEV with VPA ([@B44]; [@B46]), 1 compared LEV with LOR ([@B42]), and 1 compared LEV plus clonazepam with placebo plus clonazepam ([@B45]), One non randomized trial compared LEV with VPA was included ([@B69]). Study characteristics of included RCTs and the non randomized trial were showed in [**Table 2**](#T2){ref-type="table"}.

###### 

The characteristics of included randomized controlled trials and the observational study

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author, year   Basic characteristics of patients                                                             Intervention    Evaluation period        Follow-up                                                              Drop-out                                                                                                  Outcome measures                                                                  
  -------------- --------------------------------------------------------------------------------------------- --------------- ------------------------ ---------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ------------------ ------------------------ ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------
  [@B13]         Aged 14\~75 years old with SE uncontrolled with LOR                                           44 (27/17)      35.41 ± 16.03            IV LEV: 20 mg/kg (rate 100 mg/min) followed by maintenance doses       IV PHT: 20 mg/kg (maximum rate 50 mg/min) followed by maintenance doses                                   24 h               Follow-up to discharge   None                                  ① Primary: termination of seizure activity within 30 min\
                                                                                                                                                                                                                                                                                                                                                                                                                           ② Secondary: recurrence of seizures within 24 h, drug related AEs, neurological outcome, need for ventilatory assistance, mortality during hospitalization

  [@B22]         aged above 15 years old with SE                                                               52 (34/18)      37.8 ± 18                IV LEV: 30 mg/kg over 30 min followed by maintenance doses             IV PHT: 20 mg/kg within 30 min followed by maintenance dose                                               24h                Follow-up to discharge   None                                  ① Primary: control of seizure with no recurrence over next 24 h.\
                                                                                                                                                                                                                                                                                                                                                                                                                           ② Secondary: AEs

  [@B42]         Convulsive SE                                                                                 79 (51/28)      LEV group:\              IV LEV: 20 mg/kg infused in 15 min                                     IV LOR: 0.1 mg/kg in 10 ml saline IV in 2--4 min                                                          24 h               Follow-up to discharge   4\*                                   ① Primary: clinical seizure cessation within 30 min\
                                                                                                                               39.16 ± 21.16\                                                                                                                                                                                                                                                                              ② Secondary: 24-h seizure freedom, mortality, AEs
                                                                                                                               LOR group:\                                                                                                                                                                                                                                                                                 
                                                                                                                               38.90 ± 23.25                                                                                                                                                                                                                                                                               

  [@B44]         Aged 15\~65 years old with GCSE                                                               150 (88/62)     33.71 ± 17.00            IV LEV: 25 mg/kg over 15 minutes followed by maintenance dose          IV PHT: 20 mg/kg followed by maintenance dose IV VPA: 30 mg/kg followed by maintenance dose               24h                1 month                  1st line treatment: none.             ① Primary: seizure cessation of first AED;\
                                                                                                                                                                                                                                                                                                                                                                                                                           ② Secondary: medical complications, mortality, major AEs, functional good outcome

  [@B45]         Aged above 18 years old with GCSE                                                             136 (94/42)     LEV group:\              IV CZP + IV LEV:\                                                      IV CZP + IV Placebo:\                                                                                     35min              15 days                  Death: 7 cases^†^\                    ① Primary: cessation of convulsions within 15 min\
                                                                                                                               55 ± 18\                 1 mg CZP for 1 min with 2\~5 g LEV for 5 min                           1 mg CZP for 1 min with placebo for 5 min                                                                                                             Unexplained exfoliation: 5 cases^‡^   ② Secondary: No need of ventilatory assistance, mortality during hospitalization
                                                                                                                               Placebo group\                                                                                                                                                                                                                                                                              
                                                                                                                               53 ± 18                                                                                                                                                                                                                                                                                     

  [@B14]         Aged between 3 months and 16 years old with convulsive SE that failed first-line BZDs         233 (112/121)   3.9 ± 3.8\               IV LEV: 40 mg/kg intravenous or intraosseous LEV infusion over 5 min   IV PHT: 20 mg/kg intravenous or intraosseous PHT infusion over 20 min                                     24 h               1 month and 2 months     1 (PHT group, died)                   ① Primary: clinical cessation of seizure activity 5 min\
                                                                                                                               LEV group: 3.8 ± 3.8\                                                                                                                                                                                                                                                                       ② Secondary: clinical cessation of seizure activity 2 h, serious AEs
                                                                                                                               PHT group: 4.0 ± 3.9                                                                                                                                                                                                                                                                        

  [@B36]         Aged 6 months and 18 years old with convulsive SE that required second-line treatment         286 (147/139)   Median (IQR)\            IV LEV: 40 mg/kg over 5 min, maximum dose 2.5 g                        IV PHT: 20 mg/kg over at least 20 min, maximum dose 2 g and with a maximum infusion rate of 1 mg/kg/min   24 h               14 days                  5^\#^                                 ① Primary: time randomization to cessation of all visible signs of convulsive activity\
                                                                                                                               LEV group:\                                                                                                                                                                                                                                                                                 ② Secondary: need for further anticonvulsants after the trial treatment; serious AEs
                                                                                                                               2.7 (1.3 \~ 5.9)\                                                                                                                                                                                                                                                                           
                                                                                                                               PHT group:\                                                                                                                                                                                                                                                                                 
                                                                                                                               2.7 (1.6 \~ 5.6)                                                                                                                                                                                                                                                                            

  [@B46]         Aged above 60 years old with GCSE                                                             118 (73/45)     Overall: 67.5 ± 7.5\     IV LEV: 20--25 mg/kg over 15 min followed by maintenance dose          IV VPA: 20--25 mg/kg followed by maintenance dose                                                         24 \~ 48 h         1 month                  18                                    ① Primary: response to first line AEDs.\
                                                                                                                               LEV group: 66.6 ± 6.7\                                                                                                                                                                                                                                                                      ② Secondary: thirty-day mortality.
                                                                                                                               VPA group: 68.5 ± 8.0                                                                                                                                                                                                                                                                       

  [@B61]         Aged 3 to 12 years old with focal motor seizures and second episode of generalized seizures   100 (58/42)     Overall: NA\             IV LEV: 30 mg/kg at 5 mg/kg/min with maintenance dose                  IV PHT: 20 mg/kg at 1 mg/kg/min with maintenance dose                                                     24 h               7 days                   5 (3 in LEV, 2 PHT)                   ① Primary: absence of seizure activity within next 24 h.\
                                                                                                                               LEV group:\                                                                                                                                                                                                                                                                                 ② Secondary: changes in respiratory rate, heart rate, blood pressure, and oxygen saturation at various time points, achievement of therapeutic drug levels
                                                                                                                               7.35 ± 2.20\                                                                                                                                                                                                                                                                                
                                                                                                                               PHT group:\                                                                                                                                                                                                                                                                                 
                                                                                                                               7.03 ± 2.85                                                                                                                                                                                                                                                                                 

  [@B69]         Aged above 14 years old with refractory SE.                                                   82 (42/40)      LEV group:\              IV LEV: 30 mg/kg                                                       IV VPA: 30 mg/kg                                                                                          24 h               NA                       NA                                    ① Primary: termination of seizure activity within 30 min\
                                                                                                                               21.08 ± 9.70\                                                                                                                                                                                                                                                                               ② Secondary: seizures freedom within 24 h
                                                                                                                               VPA group:\                                                                                                                                                                                                                                                                                 
                                                                                                                               26.62 ± 10.10                                                                                                                                                                                                                                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*A total of 83 patients with SE were recruited in this study, 4 were excluded because of lack of consent, liver failure, already on study drug, and nonconvulsive SE in 1 each.

^†^Three cases died in LEV group and four cases died in placebo group.

^‡^After 15 days of follow-up, there were five cases of unexplained exfoliation: two cases in LEV group and three cases in placebo group.

^\#^Two participants in the PHT group discontinued treatment early because of loss of intravenous access during drug administration, one participant died in LEV group and one participant died in PHT group, and one participant died as a result of catastrophic cerebral edema unrelated to either treatment (this participant received LEV followed by PHT)

AE, adverse events; AED, anti-epileptic drugs; BZDs, benzodiazepines; F, female; GCSE, generalized convulsions status epilepticus; IQR, interquartile range; IV, intravenous; LEV, levetiracetam; LOR, lorazepam; M, male; NA, not available; PHT, phenytoin; SD, standard difference; SE, status epilepticus; VPA, valproate.

Study characteristics of included 27 case reports/series were showed in [**Table 3**](#T3){ref-type="table"}.

###### 

The characteristics of included case reports/series.

  Psychiatric and behavioral side effects (n = 15)   Digestive system (n = 7)   Hematological side effects (n = 3)   Kidney (n = 2)   Skin (n = 2)   Seizure aggravation (n = 2)   Others (n = 11)
  -------------------------------------------------- -------------------------- ------------------------------------ ---------------- -------------- ----------------------------- -----------------
  [@B3]                                              [@B7]                      [@B29]                               [@B1]            [@B30]         [@B15]                        [@B4]
  [@B4]                                              [@B33]                     [@B41]                               [@B5]            [@B71]         [@B47]                        [@B5]
  [@B5]                                              [@B43]                     [@B55]                                                                                             [@B6]
  [@B9]                                              [@B53]                                                                                                                        [@B33]
  [@B19]                                             [@B70]                                                                                                                        [@B31]
  [@B25]                                             [@B62]                                                                                                                        [@B38]
  [@B28]                                             [@B52]                                                                                                                        [@B41]
  [@B30]                                                                                                                                                                           [@B47]
  [@B33]                                                                                                                                                                           [@B53]
  [@B39]                                                                                                                                                                           [@B71]
  [@B41]                                                                                                                                                                           [@B58]
  [@B47]                                                                                                                                                                           
  [@B53]                                                                                                                                                                           
  [@B62]                                                                                                                                                                           
  [@B70]                                                                                                                                                                           

A total of one economic study was from the U.S. evaluating the cost-effectiveness of non-benzodiazepine AEDs (non-BZD AEDs) for treatment of BZD-resistant convulsive SE was included ([@B56]). Decision analysis model populated with effectiveness data from a SR and meta-analysis of literature, and cost data from publicly available prices. The primary outcome was cost per seizure stopped.

Generally, included SRs and economic study was of good quality, but RCTs were of unclear or high risk of bias. Of the five included SRs, two SRs were of high quality ([@B51]; [@B10]), two SRs were of moderate quality due to unclear information in 3 items and unreported information in 2 items in [@B34] while unclear information in 6 items and unreported information in 2 items in Yasiry 2014 ([@B72]), and one SR was of low quality due to unclear or unreported information in 10 of 11 items ([@B74]). The included nine RCTs were generally of unclear or high risk of bias mainly due to unclear risk of bias in allocation concealment and blinding domains, only two RCTs were of low risk of bias ([@B14]; [@B36]). The included RCTs were generally open-label randomized clinical trials, only one RCT used the double-blind design ([@B45]) and one RCT used the single-blind design ([@B46]). All included nine RCTs analyzed data with the intention-to-treat principle ([**Table 4**](#T4){ref-type="table"}). The included economic study was of high quality, as it covered most of the items specified by the CHEERS statement except descriptions of study perspective and discount rate ([@B56]).

###### 

Risk of bias of included randomized controlled trials.

  Studies   Random sequence generation   Allocation concealment   Blinding   Incomplete outcome data   Selecting reporting   Other source of bias   Total
  --------- ---------------------------- ------------------------ ---------- ------------------------- --------------------- ---------------------- ---------
  [@B13]    High                         High                     Unclear    Low                       Low                   Low                    High
  [@B22]    Low                          Unclear                  Unclear    Low                       Low                   Low                    Unclear
  [@B42]    Low                          Unclear                  Unclear    High                      Low                   Unclear                High
  [@B44]    Low                          Unclear                  Unclear    Low                       Low                   Low                    Unclear
  [@B45]    Low                          Low                      Low        Low                       Low                   High                   High
  [@B14]    Low                          Low                      Low        Low                       Low                   Low                    Low
  [@B36]    Low                          Low                      Low        Low                       Low                   Low                    Low
  [@B46]    Low                          Unclear                  Unclear    Unclear                   Low                   Low                    Unclear
  [@B61]    Low                          Low                      Unclear    Unclear                   Low                   Low                    Unclear

SE Cessation {#s3_3}
------------

Five SRs evaluated rates of SE cessation ([@B34]; [@B74]; [@B51]; [@B72]; [@B10]). One SR indicated no statistically significant difference when LEV was compared with LOR ([@B51]) as first-line treatment (risk ratio, RR= 0.97, 95% CI 0.44 to 2.13) or PHT ([@B10]) as second-line treatment (OR = 1.18, 95% CI 0.50 to 2.79). Two SRs ([@B34]; [@B10]) indicated no statistically significant difference when LEV was compared with VPA as second-line treatment (OR = 1.16, 95% CI 0.45 to 2.97, indirect comparisons; ([@B10]) and OR = 0.80, 95% CI 0.32 to 2.01) ([@B34]). One SR indicated that the efficacy of LEV ranged from 44% to 94% ([@B74]).

Meta-analyses of newly included RCTs showed no statistically significant difference in SE cessation when LEV was compared with LOR ([@B42]) (first-line treatment, OR = 1.04, 95% CI 0.37 to 2.92), PHT ([@B13]; [@B44]; [@B22]; [@B61]; [@B14]; [@B36]) (second-line treatment, OR = 0.90, 95% CI 0.64 to 1.27), and VPA ([@B44]; [@B46]) (second-line treatment, OR = 1.47, 95% CI 0.81 to 2.67). And there was no statistically significant difference when LEV plus clonazepam was compared with placebo plus clonazepam ([@B42]) (OR = 1.00, 95% CI 0.43 to 2.35) ([**Figure 2**](#f2){ref-type="fig"}).

![Rates of seizure cessation of included randomized controlled trials. Abbreviations: CLO, clonazepam; LEV, levetiracetam; LOR, lorazepam; PHT, phenytoin; VPA, valproate.](fphar-11-00751-g002){#f2}

Seizure Freedom Within 24 h {#s3_4}
---------------------------

Four RCTs ([@B42]; [@B13]; [@B14]; [@B36]) evaluated the rates of seizure freedom within 24 h and indicated no statistically significant difference in rates of seizure freedom within 24 h when LEV was compared with LOR ([@B42]) \[first-line treatment, OR = 1.83, 95% confidence interval (CI) 0.57 to 5.90\], PHT ([@B13]; [@B14]; [@B36]) (second-line treatment, OR = 1.08, 95% CI 0.63 to 1.87) ([**Figure 3**](#f3){ref-type="fig"}).

![Number of seizure freedom within 24 h of included randomized controlled trials.](fphar-11-00751-g003){#f3}

Neurological Outcome at Discharge {#s3_5}
---------------------------------

Three RCTs ([@B13]; [@B44]; [@B22]) reported the neurological outcome at discharge. The definition of good functional outcome in one RCT is 5\~7 points in functional independence measure ([@B13]) and 0\~3 points in the modified Rankin scale in two RCTs ([@B44]; [@B22]). Pooled results showed no statistically significant difference between LEV and PHT in the number of good functional outcomes at discharge (OR = 1.87, 95% CI 0.95 to 3.70) ([**Figure 4**](#f4){ref-type="fig"}).

![Number of functional good outcome at discharge of included randomized controlled trials.](fphar-11-00751-g004){#f4}

Mortality During Hospitalization {#s3_6}
--------------------------------

Seven RCTs ([@B42]; [@B13]; [@B44]; [@B45]; [@B22]; [@B14]; [@B36]) reported mortality during hospitalization. Pooled results showed no statistically significant difference in rates of mortality during hospitalization when LEV was compared with LOR (first-line treatment, OR = 1.03, 95% CI 0.31 to 3.39), PHT (second-line treatment, OR = 0.89, 95% CI 0.37 to 2.10), and VPA (second-line treatment, OR = 1.28, 95% CI 0.32 to 5.07), placebo (plus clonazepam, OR = 0.73, 95% CI 0.16 to 3.38) ([**Figure 5**](#f5){ref-type="fig"}).

![Rates of mortality during hospitalization of included randomized controlled trials.](fphar-11-00751-g005){#f5}

Discontinuation Due to Adverse Events and Serious Adverse Events {#s3_7}
----------------------------------------------------------------

The newly included RCTs showed no cases of discontinuation due to AEs.

What\'s more, the meta-analysis of newly included RCTs indicated that there was no statistically significant difference between LEV and PHT (OR = 0.65, 95% CI 0.11 to 3.96) in the rates of serious AEs ([@B14]; [@B36]), only one RCT reported serious AEs and indicated no statistically significant difference when LEV plus clonazepam was compared with placebo plus clonazepam (19/47 versus 28/47) ([@B45]).

Total Adverse Events {#s3_8}
--------------------

Among the five included SRs, only one SR ([@B74]) reported AEs and indicated sedation/somnolence as the most common AEs with rates ranging from 12.5% to 40% with LEV.

Nine RCTs ([@B42]; [@B13]; [@B44]; [@B45]; [@B22]; [@B61]; [@B14]; [@B36]; [@B46]) reported total AEs. Meta-analysis of eight included RCTs ([@B42]; [@B13]; [@B44]; [@B22]; [@B61]; [@B14]; [@B36]; [@B46]) showed no statistically significant difference when LEV was compared with LOR (OR = 1.22, 95% CI 0.37 to 4.02) ([@B42]), PHT (OR = 0.89, 95% CI 0.46 to 1.75) ([@B13]; [@B44]; [@B22]; [@B61]; [@B14]; [@B36]), and VPA (OR = 1.48, 95% CI 0.44 to 4.91) ([@B44]; [@B46]) in rates of total AEs ([**Figure 6**](#f6){ref-type="fig"}). Another RCT reported lower but no statistically significant difference total non-serious AEs of LEV plus clonazepam compared with placebo plus clonazepam (90/197 versus 107/197) ([@B45]). None of AEs led to withdrawal from drug treatment.

![Total adverse events of included randomized controlled trials.](fphar-11-00751-g006){#f6}

Single AEs {#s3_9}
----------

One RCT compared LEV plus clonazepam and placebo plus clonazepam study reported the most common AEs as respiratory disorders (32%), general disorders (19%), musculoskeletal and connective tissue disorders (12%), psychiatric disorders (12%), infections (10%), and nervous system disorders (9%) in LEV plus clonazepam group, while the most common AEs as respiratory disorders (32%), musculoskeletal and connective tissue disorders (19%), general disorders (18%), infections (16%), gastrointestinal disorders (15%), and vascular disorders (12%) in LEV plus placebo group ([@B45]).

One RCT study indicated a lower need for artificial ventilation (4/23 vs 10/21, OR = 0.23, 95% CI 0.06\~0.92) and a lower risk of hypotension (2/23 vs 8/21, OR = 0.15, 95% CI 0.03\~0.84) when LEV compared with LOR. Other AEs in LEV and LOR groups were pneumonia (8/7), thrombocytopenia (4/1), agitation (4/0), liver dysfunction (0/2), rash (1/0), and urinary infection (0/1), with no statistic difference ([@B42]).

Six included RCTs ([@B13]; [@B44]; [@B22]; [@B61]; [@B14]; [@B36]) compared the incidence of single AEs for LEV and PHT. Four of these studies ([@B13]; [@B44]; [@B22]; [@B36]) indicated that LEV had a trend of lower risk of hypotension compared with PHT (OR = 0.34, 95% CI 0.10\~1.21); while two included RCTs ([@B22]; [@B36]) indicated that LEV had a trend of higher risk of agitation (OR = 2.86, 95% CI 0.95\~8.59).

One RCT indicated that LEV had a trend of higher risk of hallucinations compared with VPA (3/50 vs 0/50) ([@B44]). Another RCT indicated that LEV had a lower risk of hepatic dysfunction (0/58 vs 1/60) compared with VPA, but no difference was found ([@B46]). One non randomized trial showed that no AEs such as hepatic dysfunction, hypotension, abnormal behavior, depressed respiratory, or thrombocytopenia occurred in any group ([@B69]).

Among the 27 case reports/series, 15 reported psychiatric and behavioral AEs and 7 reported gastrointestinal AEs. Rates of behavioral AEs (such as aggression and irritability) varied from 1.1% to 15% and nausea/vomiting varied from 3.1% to 5.6% ([**Table 2**](#T2){ref-type="table"}).

Cost-Effectiveness {#s3_10}
------------------

One cost-effectiveness evaluation for BZD-resistant convulsive SE with decision analysis model was conducted in the US ([@B56]). The economic study showed the most cost-effective non-BZD AED was LEV (incremental cost-effectiveness ratio, incremental cost-effectiveness ratio, ICER: \$18.55/seizure-stop), followed by VPA (ICER: \$94.44/seizure-stop), and lastly PB (ICER: \$847.22/seizure-stop). PHT and lacosamide were not cost-effective compared to the other options. Probabilistic sensitivity analysis indicated that LEV was the most cost-effective strategy in most second-order Monte Carlo simulations for a willingness to pay between approximately \$25/seizure-stop and \$100/seizure-stop.

Discussion {#s4}
==========

The present study indicated that LEV had similar efficacy in SE cessation and mortality during hospitalization compared with LOR, PHT and VPA; no statistically significant difference in rates of seizure freedom within 24 h compared with LOR and PHT, as well as number of good functional outcome at discharge compared with PHT. Concerning safety, no statistically significant difference among LEV, LOR, PHT, and VPA in rates of total AEs was found. However, LEV had a lower risk of hypotension and requirement for ventilator assistance compared with LOR and PHT.

Available IV AEDs are limited in clinical practice. Considering AEs of AEDs, one medication may be preferable for patients. Hong Kong Epilepsy Guideline suggested that IV LEV can be considered as an alternative to PHT in benzodiazepine-resistant SE, such as established SE ([@B27]; [@B20]; [@B35]). The National Institute for Health and Care Excellence guideline suggested that LEV are potentially as effective as PB and safer for SE ([@B35]). Compared with VPA, PHT and lacosamide, LEV was the first choice drug for IV administration of SE, according to a Germany chart review ([@B27]).

In this study, we collected the most comprehensive evidence of IV LEV, while safety profiles were often missed in the previous studies ([@B74]; [@B51]; [@B72]; [@B13]). Second, types of literature included in the study include SRs, RCTs, and observational studies. The study can provide reliable evidence for physicians or policymakers.

There are still some limitations to this study. First, only English-language studies were included. Moreover, the included RCTs were of unclear or high risk of bias. SE needs rapid termination of seizure activity to minimize neurological injury and systemic dysfunction, so it is difficult to achieve strict and consistent randomized control. However, although most of the included RCTs were not double-blinded, the judgment of some outcomes, such as SE cessation was not influenced. Third, no subgroup analysis of different types of SE such as convulsive SE, non-convulsive forms of SE were conducted due to limited studies included.

Considering the complexity of SE and the relatively high incidence of complications, the management of SE and its pharmacological treatment still need more high quality evidence to inform clinical practice and decision making.

Conclusions {#s5}
===========

IV LEV can be used as a second-line treatment for SE. For patients with SE, LEV has similar efficacy with LOR, PHT, and VPA, and a lower risk of hypotension and requirement for ventilator assistance compared with LOR and PHT. Regarding tolerability, LEV also showed good qualities for it does not increase risks of serious AEs or discontinuation from studies due to AEs in current researches. However, there is still a lack of evidence to support its cost-effectiveness, and more studies are needed to confirm its role for SE.
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